Acurx Pharmaceuticals, Inc. to Discuss 2022 First Quarter Financial Results on May 11, 2022 Conference Call and Provide Business Update
Acurx Pharmaceuticals (NASDAQ: ACXP) will release its 2022 Q1 financial results on May 11, 2022, at 8:30 am ET. Following the results, a conference call will be held where CEO David P. Luci and CFO Robert G. Shawah will provide updates. The company is advancing its antibiotic ibezapolstat for treating C. difficile infections, with successful Phase 1 and 2a trials showing 100% clinical cure rates. Ibezapolstat has received FDA designations for streamlined development due to the urgent need for new treatments.
- 100% clinical cure and sustained clinical cure rates in Phase 2a trials of ibezapolstat for C. difficile.
- Ibezapolstat designated as a Qualified Infectious Disease Product by the FDA, eligible for incentives.
- Fast Track designation granted by the FDA for ibezapolstat to expedite its development.
- Dependence on clinical trial results for future approvals and marketing of ibezapolstat.
- Market risks including potential delays in clinical trials or unfavorable trial results.
STATEN ISLAND, N.Y., April 29, 2022 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that the Company will release its 2022 first quarter financial results on Wednesday, May 11 2022, at 8:30 am ET before the U.S. financial markets open.
David P. Luci, President and Chief Executive Officer, and Robert G. Shawah, Chief Financial Officer, will host a conference call to discuss the results and provide a business update as follows:
Date: | Wednesday, May 11, 2022 | |
Time: | 8:30 a.m. ET | |
Toll free (U.S.): | 877-790-1503 | |
International: | Click here for participant international Toll-Free access numbers https://www.incommconferencing.com/international-dial-in | |
Conference ID: | 13729712 |
About Ibezapolstat
Ibezapolstat is a novel, orally administered antibiotic being developed as a Gram-Positive Selective Spectrum (GPSS™) antibacterial. It is the first of a new class of DNA polymerase IIIC inhibitors under development by Acurx to treat bacterial infections. Ibezapolstat's unique spectrum of activity, which includes C. difficile but spares other Firmicutes and the important Actinobacteria phyla, appears to contribute to the maintenance of a healthy gut microbiome.
The Company successfully completed Phase 1 and Phase 2a clinical trials of ibezapolstat. The Phase 2a trial demonstrated
In June 2018, ibezapolstat was designated by the U.S. Food and Drug Administration (FDA) as a Qualified Infectious Disease Product (QIDP) for the treatment of patients with CDI and will be eligible to benefit from the incentives for the development of new antibiotics established under the Generating New Antibiotic Incentives Now (GAIN) Act. In January 2019, FDA granted "Fast Track" designation to ibezapolstat for the treatment of patients with CDI. The CDC has designated C. difficile as an urgent threat highlighting the need for new antibiotics to treat CDI.
About Acurx Pharmaceuticals, Inc.
Acurx Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing new antibiotics for difficult to treat infections. The Company's approach is to develop antibiotic candidates that target the DNA polymerase IIIC enzyme and its R&D pipeline includes antibiotic product candidates that target Gram-positive bacteria, including Clostridioides difficile, methicillin-resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococcus (VRE) and drug-resistant Streptococcus pneumoniae (DRSP).
To learn more about Acurx Pharmaceuticals and its product pipeline, please visit www.acurxpharma.com.
Forward-Looking Statements
Any statements in this press release about our future expectations, plans and prospects, including statements regarding our strategy, future operations, prospects, plans and objectives, and other statements containing the words "believes," "anticipates," "plans," "expects," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: whether ibezapolstat will benefit from the QIDP designation; whether ibezapolstat will advance through the clinical trial process on a timely basis; whether the results of the clinical trials of ibezapolstat will warrant the submission of applications for marketing approval, and if so, whether ibezapolstat will receive approval from the FDA or equivalent foreign regulatory agencies where approval is sought; whether, if ibezapolstat obtains approval, it will be successfully distributed and marketed; and other risks and uncertainties described in the Company's annual report filed with the Securities and Exchange Commission on Form 10-K for the year ended December 31, 2021, and in the Company's subsequent filings with the Securities and Exchange Commission. Such forward-looking statements speak only as of the date of this press release, and Acurx disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances after the date of such statements, except as may be required by law.
Investor Contact:
Acurx Pharmaceuticals, Inc.
David P. Luci, President & CEO
Tel: 917-533-1469
Email: davidluci@acurxpharma.com
View original content:https://www.prnewswire.com/news-releases/acurx-pharmaceuticals-inc-to-discuss-2022-first-quarter-financial-results-on-may-11-2022-conference-call-and-provide-business-update-301536097.html
SOURCE Acurx Pharmaceuticals, Inc.
FAQ
What date will Acurx Pharmaceuticals announce its Q1 2022 financial results?
What are the results of the Phase 2a trial for ibezapolstat?
What FDA designations has ibezapolstat received?
When is the conference call to discuss Acurx's Q1 results?
